Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Xu Hu

Senior Reporter

Xu is a senior reporter and covers aspects on policy and regulations in China pharma industry within the APAC Pharma news team.

Xu is passionate about understanding information and knowledge related to biopharma industry. She is bilingual in Mandarin and English. Prior to this, Xu worked as a medical writer and wrote publications based on data from clinical trials for a wide range of therapeutic areas for global pharmaceutical companies. She holds a Master degree in Medical Pharmaceutical Science from University of Groningen and a PhD degree in Biomedical Science from Vrije Universiteit Amsterdam in the Netherlands.

Latest From Xu Hu

Asia Deal Watch: EpimAb Licenses Bispecific Antibody To Newly Formed Vignette

Also including deals between EpimAb/Vignette, Allist/Jacobio, Rigel/Kissei, Simcere/TargetRx, Altamira/Nuance, PharmaEssentia/Forus and Chugai/LTL.

Deal Watch Business Strategies

Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

Clinical Trials Research & Development
See All
UsernamePublicRestriction

Register